Access gates tighten, workflow owners win, and pathology platforms scale across borders

EviCore Turns Guardant Shield Coverage Into a State-by-State Access Play

EviCore’s expansion of coverage for Guardant Health’s FDA-approved Guardant Shield colorectal cancer blood test shows how access is now being operationalized in stages: effective January 1, 2027, Shield will be covered under EviCore clinical guidelines for eligible policyholders in 23 states, for average-risk adults 45 and older. The move is specific but bounded; the available sources do not show changes to prior authorization or reimbursement rates, only guideline-based coverage. Peerbridge’s FDA clearance for Cor MDx reinforces the point that regulatory progress is necessary, but not enough to drive commercial velocity.

The bottleneck is shifting from clearance to payment infrastructure. Medicare’s PAMA-based Clinical Laboratory Fee Schedule still anchors diagnostic pricing, while CMS is capping annual CLFS cuts at 15% for 2027-2029 after earlier reductions that critics say removed roughly $4 billion from 2018-2020. CMS is also proposing to move certain algorithmic and molecular analyses out of the CLFS and into physician or outpatient payment systems, and its proposed Software as a Medical Service category signals a payment framework that favors diagnostics embedded in longitudinal care but demands tighter coding discipline.

For operators and vendors, commercialization now depends on coverage execution as much as assay performance. For investors, value is concentrating in companies that pair FDA progress with guideline inclusion, coding resilience, and recurring-care fit.

Capital and Partnerships Now Favor the Workflow Owners

Fuse Diagnostics raised £1M to commercialize its Flip molecular diagnostic platform for point-of-need testing, while Hedera Dx secured a €15M Series A to scale decentralized, hospital-run liquid biopsy testing. Aptitude Medical Systems also received about $10M from the Gates Foundation to expand decentralized molecular STI testing, and SOPHiA GENETICS and AstraZeneca launched a partnership to develop two decentralized companion diagnostics for precision oncology. The common thread is that the next layer of defensibility is no longer just assay performance, but the ability to sit inside repeat clinical workflows.

Wisp’s expansion to 2 million patients across all 50 states extends that pattern in women’s health, where fertility, menopause/perimenopause, skincare, weight care, OTC supplements, and diagnostics are bundled with at-home testing, telehealth, and follow-up prescribing. Tempus’ million-genome clinical data platform, along with continued momentum around Natera and GRAIL, reinforces the same moat structure: distribution plus data compounding now matter as much as test quality. For practitioners, the question is increasingly who owns the patient, workflow, and follow-up data once testing leaves the core lab; for vendors and investors, pricing power is shifting toward companies that can combine regulatory clearance with repeat utilization and expanding real-world datasets.

Unilabs Turns Enterprise Pathology Standardization Into a Multi-Country Rollout

Unilabs’ Europe-wide rollout of Proscia’s Concentriq AP-Dx is the clearest sign yet that the enterprise layer is no longer theoretical: multiple countries are already live, with more scheduled before year-end. The deployment is phased, not a full workflow rip-and-replace, but it shows routine digital pathology case review being organized around a single enterprise environment that connects pathologists, lab sites, diagnostic data, and AI applications, with AP-Dx positioned for primary diagnosis when paired with specified interoperable components.

The competitive field is converging on the same control point through different architectures. MGI’s VisiOmics bundles automated multiplex immunofluorescence staining, tissue imaging, and embedded AI analysis through FluoXpert Vision, reducing dependence on third-party tools. Sectra is leaning on shared multi-hospital access to improve pathologist utilization and support cancer diagnostics workflows, including biomarker assessment. For practitioners, the progression from workflow infrastructure to enterprise operating layer means procurement is increasingly about which platform can standardize throughput across sites, preserve interoperability, and expand into the broader pathology operating layer without fragmenting daily case review.